A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl aurista...

Full description

Saved in:
Bibliographic Details
Main Authors: Anders H. Hansen, Kasper I. H. Andersen, Li Xin, Oliver Krigslund, Niels Behrendt, Lars H. Engelholm, Claus H. Bang-Bertelsen, Sanne Schoffelen, Katrine Qvortrup
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Molecules
Subjects:
breast cancer
targeted treatment
nanobody
site-selective conjugation
Online Access:https://www.mdpi.com/1420-3049/30/2/391
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1420-3049/30/2/391

Similar Items